ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

10,740Medicare Part D Prescriptions Filled, Including Refills

Rank: 60 out of 337

$610K Total Retail Price of All Prescriptions

Rank: 43 out of 337

408 Patients Receiving at Least One Drug in Part D
90%Patients 65 Years and Older
27% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Rhode Island
Lower avg

Schedule Two
Controlled Substances

3% of this provider’s 408 patients filled at least one prescription for a schedule two drug, compared to an average of 4%.

Schedule Three
Controlled Substances

8% of this provider’s 408 patients filled at least one prescription for a schedule three drug, compared to an average of 7%.

Risky Drugs to Seniors

1% of this provider’s 9,900 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

28% of this provider’s prescriptions were for brand-name drugs, compared to an average of 22%.

Prescription Price

$57 was the average price of a prescription from this provider, compared to $51 among peers.

Prescriptions per Patient

26 is the average number of prescriptions (including refills) per patient, compared to an average of 22.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Rhode Island
LISINOPRIL 476 455 1 2
SIMVASTATIN 458 414 2 1
ATORVASTATIN CALCIUM 413 372 3 7
OMEPRAZOLE 381 357 4 4
CRESTOR 341 323 5 29
LEVOTHYROXINE SODIUM 338 315 6 5
AMLODIPINE BESYLATE 319 297 7 3
FUROSEMIDE 263 246 8 8
METOPROLOL TARTRATE 242 232 9 6
ATENOLOL 233 207 10 10
HYDROCHLOROTHIAZIDE 217 208 11 9
CITALOPRAM HBR 216 210 12 17
METFORMIN HCL 183 150 13 12
HYDROCODONE-ACETAMINOPHEN 168 107 S3 14 13
LISINOPRIL-HYDROCHLOROTHIAZIDE 159 153 15 31
TRAZODONE HCL 153 153 16 16
ALENDRONATE SODIUM 145 140 17 19
QUINAPRIL HCL 144 135 18 50
FLUOXETINE HCL 144 125 18 57
WARFARIN SODIUM 138 138 20 11
RANITIDINE HCL 133 117 21 30
LOSARTAN POTASSIUM 118 111 22 15
NAMENDA 114 114 23 35
EVISTA 114 114 23 102
SERTRALINE HCL 113 113 25 18
DONEPEZIL HCL 112 112 26 22
METOPROLOL SUCCINATE 102 97 27 21
MELOXICAM 97 85 28 54
BYSTOLIC 93 58 29 91
MIRTAZAPINE 93 89 29 27
ZOLPIDEM TARTRATE 92 61 31 23
SYNTHROID 92 92 31 41
CYMBALTA 92 90 31 59
ALLOPURINOL 91 76 34 28
LIPITOR 90 79 35 33
GLIPIZIDE ER 87 87 36 69
FENOFIBRATE 83 65 37 48
DOXAZOSIN MESYLATE 80 80 38 68
LEVOXYL 79 79 39 90
FLUTICASONE PROPIONATE 69 69 40 34
EXELON 69 69 40 85
TRAMADOL HCL 68 68 42 32
LOSARTAN-HYDROCHLOROTHIAZIDE 67 67 43 60
QUETIAPINE FUMARATE 66 66 44 61
TRIBENZOR 66 60 44 224
BENICAR HCT 61 55 46 166
PRAVASTATIN SODIUM 55 51 47 14
NIFEDIPINE ER 51 51 48 111
TAMSULOSIN HCL 50 49 49 25
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Feb. 1, 2011.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.